Navigation Links
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Date:5/31/2008

mTOR inhibitor approved to treat RCC. TORISEL specifically inhibits the mTOR kinase, an important regulator of cell proliferation, cell growth and cell survival and is the only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced RCC.

Study Design and Results

This three-arm, open-label, randomized, phase 3 trial compared two different dose regimens of TORISEL with investigators' choice of therapy (IC) in patients with relapsed or refractory MCL who had received two to seven prior therapies, which could include hematopoietic stem cell transplantation. Patients were randomly assigned to receive intravenous (IV) TORISEL at 175 mg for three successive weekly doses followed by 75 mg IV weekly; TORISEL 175 mg IV for three successive weekly doses followed by 25 mg IV weekly; or investigators' choice of one of the following single agents at predefined doses: gemcitabine, fludarabine, chlorambucil, cladribine, etoposide, cyclophosphamide, thalidomide, vinblastine, alemtuzumab or lenalinomide. The primary end point was PFS based on independent review. Secondary end points were objective response rate and overall survival.

Median PFS for patients treated with TORISEL 175 mg/75 mg was 4.8 months, compared with 1.9 months for patients treated with IC. In the TORISEL 175 mg/25 mg arm, median PFS was 3.4 months, but this difference was not statistically different from IC (P=0.0618).

Patients receiving TORISEL 175 mg/75 mg showed a nonsignificant trend toward longer overall survival than those treated with IC (13.6 months vs. 9.7 months; HR=0.80). TORISEL 175 mg/75 mg led to a statistically significant improvement over IC in objective response rates (22 percent vs. 2 percent, P=0.0019).

The most frequently occurring grade 3 or 4 adverse events among patients treated with TORISEL 175 mg/75 mg, TORISEL 175 mg/25 mg, or IC were thrombocytopenia (59 percent vs. 52 percent vs. 36 percent
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
3. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
4. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
7. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. Tailored Clopidogrel Dosing Improves PCI Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... determining factor, study finds , , TUESDAY, Jan. 22 (HealthDay ... for fast-moving prostate cancer can save lives, but the ... serious medical problems, a new study shows. , "The ... is a difference in outcome, depending on the gentleman,s ...
... pounds than dieting and exercise do, study shows , , ... gastric lap-band surgery isn,t only for the most obese; it ... , Still, the surgery is extremely expensive and carries risks. ... need alternative ways to shed pounds, said study author John ...
... MENTOR, Ohio, Jan. 22 STERIS Corporation,(NYSE: STE ... authorized a,regular quarterly dividend in the amount of $0.06 ... to shareholders of record at the close,of business on ... of STERIS Corporation is to provide a healthier today ...
... of Navarra PhD in chemistry researcher, Esther Vicente, has ... Her thesis, defended at the Faculty of Sciences in ... describes the synthesis and characterisation of 65 derivatives of ... number of antimalalarial and antituberculosis pharmaceutical drugs currently on ...
... January 22, 2007, Weinheim, DE: Wiley-Blackwell, the scientific, ... Wiley & Sons, Inc., published a comprehensive resource ... function. , Proteins are essential components of all ... and function of each cell and, ultimately, the ...
... how to manipulate the immune system to increase its ... , Published in the current edition of Viral ... new and more effective vaccines against diseases like influenza ... , The study suggests that scientists can boost the ...
Cached Medicine News:Health News:Hormone Therapy Only Helps Some Older Men With Prostate Cancer 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3Health News:Research discovers new compounds active against tuberculosis and malaria 2Health News:'The Handbook of Proteins' 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: